Company	Price	Valuation					Profitability					Cash & leverage					Quality				Rating
		P/E	P/B	P/S	EV / EBITDA	DCF upside	Gross margin	Operating margin	Net margin	ROE	ROIC	FCF yield	Debt / equity	Net debt / EBITDA	Interest coverage	Current ratio	Dividend yield	Piotroski (0-9)	Altman Z	Rating score (1-5)
SNDXthis companySyndax Pharmaceuticals, Inc.	$9.58	-6.39×	28.16×	10.56×	-8.07×	-0.0%	96.0%	-158.4%	-165.6%	-441.6%	-66.6%	-17.8%	5.36×	-0.84×	-8.08×	4.4×	0.0%	3	-1.72	1	D+
ALXOALX Oncology Holdings Inc.	$1.22	-0.59×	2.33×	0×	-0.5×	-90.6%	0.0%	0.0%	0.0%	-391.4%	-262.0%	-139.1%	0.2×	0.11×	-64.93×	2.07×	0.0%	2	-2.66	2	C
CTMXCytomX Therapeutics, Inc.	$2.08	-28.4×	5.93×	7.71×	-36.76×	-283.4%	100.0%	-29.3%	-22.8%	-17.5%	-20.5%	-12.9%	0.04×	0.53×	0×	3.09×	0.0%	1	1.34	2	C
MGNXMacroGenics, Inc.	$2.44	-1.36×	1.83×	0.68×	-2.54×	-2714.5%	71.1%	-48.7%	-49.9%	-134.2%	-33.0%	-81.6%	1.92×	-0.83×	-8.56×	5.1×	0.0%	1	-4.43	1	D+
NRIXNurix Therapeutics, Inc.	$15.81	-5.54×	2.72×	17.45×	-5.2×	-213.0%	77.5%	-340.2%	-314.9%	-49.1%	-47.3%	-18.0%	0.1×	0.78×	0×	7.02×	0.0%	7	9.1	4	A-
NUVBNuvation Bio Inc.	$4.32	-14.93×	10.01×	48.65×	-15.36×	-33.1%	86.6%	-338.7%	-325.3%	-66.9%	-41.0%	-5.7%	0.03×	0.81×	-15.57×	6.95×	0.0%	3	0.52	1	C-
Peer median	—	-5.54×	2.72×	7.71×	-5.2×	-213.0%	77.5%	-48.7%	-49.9%	-66.9%	-41.0%	-18.0%	0.1×	0.53×	-8.56×	5.1×	0.0%	2	0.52	2	—